Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases. The deal could be worth up ...

Novo Nordisk and Septerna plan to create new obesity pills that target G protein-coupled receptors (GPCRs), including GLP-1, GIP, and glucagon. HealthDay News — Danish drugmaker Novo Nordisk is ...

Wegovy maker Novo Nordisk has hired the start-up Deep Apple Therapeutics to develop small molecules as its next weight-loss ...

Here's a recap of the week's most important stories. NVO to Co-Develop Septerna's Oral Therapies for Obesity/Diabetes Novo Nordisk signed a licensing deal with Septerna to co-develop oral ...

Novo Nordisk and Septerna will jointly carry out research on the candidates from discovery to development candidate selection, with the Danish pharma group taking over responsibility as they ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

(Bloomberg) -- Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity in a deal potentially worth up to $2.2 billion. The two companies will ...

Danish pharmaceutical giant Novo Nordisk and U.S. biotech Septerna agreed to collaborate on the development of pills to treat obesity, type 2 diabetes and other metabolic conditions. Under the ...

HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases.

Major Partnership With Novo Nordisk Could Boost Septerna Septerna Inc (NASDAQ:SEPN) is a clinical-stage biotechnology firm developing G protein-coupled receptor (GPCR) oral small molecule drug ...

On May 14, 2025, Septerna announced a global collaboration with Novo Nordisk to discover and develop oral small molecule therapies for obesity, type 2 diabetes, and cardiometabolic diseases.